By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...
Shanghai: China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese ...
Less than two weeks after Pfizer struck a deal with a Chinese drugmaker to gain commercial rights to a GLP-1 drug, the ...
One of the most powerful voices in the biopharma industry, Pfizer CEO Albert Bourla, Ph.D., has weighed in with sharp ...
Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.
Pfizer CEO Albert Bourla on Monday flagged issues with the leadership of the U. Food and Drug Administration's vaccine ...
NEW YORK, March 5 (Reuters) - A federal judge on Thursday awarded Pfizer $29 million to resolve a dispute with the U.S. Securities and Exchange Commission stemming from the regulator's 2013 insider ...
Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.
A Pfizer Inc. contract provision requiring employees to keep the subject and materials of arbitration proceedings ...
A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...
Those were in great demand at the beginning of the pandemic, and generated gobs of money for Pfizer. Demand has waned, though ...
SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, the US drugmaker said on WeChat on Friday, boosting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results